SRK-373 / Scholar Rock - LARVOL DELTA

Scholar Rock to Present New Preclinical Data on its Targeted Approach to the LTBP-TGFβ1 Complex for Anti-Fibrotic Therapy at the 2022 FASEB Science Research Conference (Businesswire) - "Scholar Rock...today announced the company will present new data that highlight the development of its highly selective, context-dependent TGFβ1 antibody that inhibits proTGFβ1 activation selectively in the context of its extracellular matrix presenting partner, latent TGFβ binding protein ('LTBP'; the target is collectively identified as 'LTBP-TGFβ1'). The data show reduction of TGFβ1 signaling and reduction of fibrosis in relevant preclinical models in vivo. These findings will be presented in an oral and poster presentation at the 2022 FASEB Science Research Conference (SRC), taking place between July 17–21, 2022 in Malahide, Ireland."

Preclinical • Cystic Fibrosis